Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases

Moderna’s mRNA Candidate Joins FDA’s Accelerator Program for Rare Diseases

Source: 
BioSpace
snippet: 

Moderna on Thursday announced that the FDA has selected its investigational methylmalonic acidemia therapy mRNA-3705 for the agency’s Support for Clinical Trials Advancing Rare Disease Therapeutics pilot program.